Sepsis Scout
Winter 2018AcquiredWearables and AI to predict and prevent sepsis outside the hospital
Pressure-test this opportunity
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Wearables and AI to predict and prevent sepsis outside the hospital
Explore the risks and possibilities with a prompt for ChatGPT, Claude, or your agent.
Sepsis Scout (originally Patchd Medical) was a San Francisco-based medical technology startup founded in 2017 by Robert Quinn and Wei-Jien Tan. The company aimed to build a wearable patch that monitored vital signs in real-time and used deep learning algorithms to predict sepsis onset in high-risk patients outside the hospital. It participated in Y Combinator's Winter 2018 batch with a team of five people and raised approximately $2.88M in total funding before being acquired by Cytovale in October 2024.[1][8]
The company failed because it pursued a continuous-monitoring wearable for at-home sepsis detection that required FDA clearance and clinical adoption it never achieved. With only $2.88M raised and no disclosed revenue or clinical validation, Sepsis Scout lacked the runway to navigate the regulatory and adoption barriers inherent to medical devices. Its eventual acquisition by Cytovale—which had a superior FDA-cleared blood-based test—rendered Sepsis Scout's technology redundant, making the deal a talent and IP acquisition rather than a strategic product merger.
Image 1 / 2
Robert Quinn's path to Sepsis Scout began with a kidney transplant that left him with an acute bout of sepsis. Since then, he has suffered 18 episodes of the disease, which causes 1 in 5 deaths globally.[4] Rather than accept this as his fate, Quinn channeled his experience into building technology for early detection. In a 2022 podcast interview, Quinn explained his motivation: "A kidney transplant left me with an acute bout of sepsis. Since then I have suffered 18 episodes of this disease, which causes 1 in 5 deaths globally. Rather than take things lying down I started a company that is creating tech that can detect sepsis in its early stage, potentially saving millions of lives."[4]
Quinn's technical background combined mechatronics engineering and biomedical science from The University of Queensland, with stints as an Implant Engineer at Cochlear (2014–2015) and an Engineer at Telstra (2016–2017).[21] His co-founder, Wei-Jien Tan, brought complementary depth in machine learning and implantable medical devices. Tan had worked in a neuroscience lab applying ML to electrophysiological measurements from rat and monkey brains, then moved to implantable medical devices as an engineer writing firmware and doing electronic design.[3]
The two met while working in the implantable medical device space, where Tan was an engineer. According to Tan's YC profile, he "met cofounder Rob Quinn there and they started Patchd Medical which became Sepsis Scout."[3] The company was founded in 2017 in San Francisco under the name Patchd Medical, later renamed Sepsis Scout.[1]
The initial vision was ambitious: continuous monitoring of high-risk patients—particularly cancer patients—at home, using off-the-shelf wearables integrated with proprietary deep learning algorithms to predict sepsis onset before symptoms manifest.[7] The company filed two patents to protect its approach: one in February 2018 for subject monitoring (WO-2019165004-A1) and another in August 2019 for sepsis detection and monitoring (US-20210052218-A1).[15]
Sepsis Scout's core product was a wearable patch designed to monitor vital signs continuously in real-time for high-risk patients. The patch tracked heart rate, respiration rate, blood pressure, temperature, and SpO2 (blood oxygen saturation), transmitting this data to a cloud-based deep learning algorithm for sepsis risk assessment.[5]
The company's proprietary algorithm analyzed micro-variations in vital signs and other physiological parameters to predict the onset of sepsis well before its symptoms manifest.[6] This was the core insight: sepsis produces subtle physiological changes hours before clinical symptoms appear, and continuous monitoring could theoretically catch these signals earlier than intermittent human observation.
The initial focus was on cancer patients at home—a population particularly vulnerable to sepsis due to immunosuppression from chemotherapy. The company's approach used off-the-shelf wearables integrated with proprietary algorithms, rather than building custom hardware from scratch.[7] This was a pragmatic choice that reduced hardware development costs but created its own challenges around sensor quality and data consistency.
The user experience was designed for passive monitoring: a patient would wear the patch continuously, and the algorithm would alert clinicians or caregivers if sepsis risk crossed a threshold. This was a fundamentally different paradigm from the standard approach to sepsis detection, which relies on periodic vital sign checks and blood tests in hospital settings.
The company filed two patents to protect its intellectual property. The first, "Systems and methods for subject monitoring" (WO-2019165004-A1), was filed in February 2018. The second, "Systems and methods for sepsis detection and monitoring" (US-20210052218-A1), was filed in August 2019.[15] These patents covered the algorithmic approach to detecting sepsis from continuous physiological data.
What made Sepsis Scout different from alternatives was its focus on the outpatient setting. Most sepsis detection tools at the time were designed for hospital use—either as part of electronic health record algorithms or as point-of-care blood tests. Sepsis Scout's bet was that the highest-value intervention point was catching sepsis before a patient needed to be hospitalized, particularly for vulnerable populations like cancer patients.
Sepsis Scout's primary target was high-risk patients at home, with an initial focus on cancer patients. The company's pitch was that these patients, due to immunosuppression from treatment, faced elevated sepsis risk and would benefit from continuous monitoring between clinical visits. The secondary customer was the clinicians and health systems managing these patients, who would receive alerts from the algorithm.
Sepsis is a massive global health problem. It causes 1 in 5 deaths globally, making it one of the leading causes of mortality worldwide.[4] The addressable market for sepsis detection tools is substantial, encompassing hospitals, outpatient clinics, and home health settings. However, the specific market for at-home continuous sepsis monitoring was nascent and unproven, with no established reimbursement pathway or clinical protocol.
The competitive landscape for sepsis detection was crowded and structurally unfavorable to a startup like Sepsis Scout. The market was dominated by two categories of players:
Hospital-based solutions. Established companies like Epic and Cerner had integrated sepsis prediction algorithms into their electronic health record systems. These tools leveraged the vast data already collected in hospital settings—lab results, vital signs, medication records—to flag at-risk patients. Their advantage was distribution: they were already installed in thousands of hospitals and had access to decades of clinical data. Sepsis Scout's wearable approach, by contrast, required new hardware adoption and generated data that had no established clinical interpretation protocol.
Point-of-care blood tests. Companies like Cytovale, Sepsis Scout's eventual acquirer, were developing rapid blood-based tests that could provide sepsis risk in minutes. Cytovale's IntelliSep test, which received FDA clearance, provides sepsis risk results in about 8 minutes from a standard blood draw.[13] This approach had a critical advantage: it leveraged existing clinical workflows (blood draws are routine in hospitals) and provided a definitive, lab-validated result that clinicians could act on with confidence.
The structural problem for Sepsis Scout was that it was competing on a dimension—continuous physiological monitoring—where incumbents and alternative approaches had natural advantages. Hospital EHR algorithms had distribution and data. Blood tests had clinical validity and workflow integration. Sepsis Scout's wearable required patients to adopt and wear a device, required clinicians to trust an algorithm's output without a confirmatory lab test, and required regulatory clearance that would take years and tens of millions of dollars to obtain.
The competitive landscape also shifted because of platform moves. As EHR vendors integrated sepsis prediction natively, the marginal value of a standalone wearable-based prediction tool diminished. And as blood-based tests like IntelliSep gained FDA clearance and commercial traction, the clinical community had a validated, actionable alternative that didn't require patients to wear anything.
Sepsis Scout never disclosed revenue, and no public information suggests the company generated meaningful commercial traction. The absence of revenue data is itself a signal: a company with a working product and paying customers would have highlighted that traction in fundraising materials or press coverage.
The company's funding history tells a clear story about its business model challenges. Total funding was approximately $2.88M across multiple rounds.[8] This included a $75K accelerator round in December 2017, a $120K Y Combinator round in March 2018, and a seed round in August 2018.[9] Investors included Y Combinator, Kapor Capital, muru-D, Allectus Capital, Colorful Capital, Constellar Ventures, Gaingels, and HHS.[10]
The funding pattern is telling. After the seed round in August 2018, the company's next funding event was a grant/prize round from HHS in August 2022—four years later.[19] This suggests the company was unable to raise additional venture capital after its seed round, likely due to lack of traction or a clear path to market. The shift to non-dilutive grant funding in 2022 is a strong indicator that traditional investors had lost confidence.
Based on the funding data, we can make directional inferences about the company's burn rate. With $2.88M raised and a team of five people, the company likely had an annual burn rate of $500K–$800K (inference based on typical startup salaries and operating costs for a team of that size in San Francisco). This would have given the company roughly 3–5 years of runway from its seed round, which aligns with the timeline from founding (2017) to the HHS grant (2022) and eventual acquisition (2024).
Public data on Sepsis Scout's traction is extremely limited. The company participated in the MedTech Innovator program in 2019, with an overview video published in August 2019.[17] This indicates some early ecosystem recognition, but the program is a competition and accelerator for medical device startups, not a validation of commercial traction.
No revenue, user, hospital partnership, or clinical trial metrics were found in public sources. The company's Crunchbase profile lists its operating status as "Closed," and its legal name as "Sepsis Scout, Inc.," also known as "Patchd."[22]
The most significant signal of limited traction is the funding gap between the August 2018 seed round and the August 2022 HHS grant. A company with strong clinical validation or commercial traction would have been able to raise a Series A during this period. The fact that Sepsis Scout's only post-seed funding was a government grant strongly suggests the company failed to achieve the milestones investors required for follow-on funding.
Sepsis Scout's fundamental problem was that it built a medical device that required FDA clearance but never had the resources to obtain it. The company's product—a wearable patch with an algorithm that predicted sepsis onset—was squarely within FDA jurisdiction as a medical device. Without FDA clearance, the company could not market the product for clinical use, could not generate revenue, and could not attract the venture capital needed to fund the regulatory pathway.
The economics of FDA clearance for medical devices are brutal. A typical Class II device submission requires clinical validation studies, quality management systems, and regulatory expertise—costs that routinely run into the tens of millions of dollars and take multiple years. Sepsis Scout raised $2.88M total.[8] That is roughly 1–5% of what a successful medical device startup typically needs to reach commercial launch.
The company's attempt to address this was to participate in the MedTech Innovator program in 2019, which provides mentorship and industry connections but no significant funding.[17] This was a reasonable move for a cash-constrained startup, but it couldn't solve the fundamental capital gap.
Even before regulatory clearance, Sepsis Scout needed clinical evidence that its algorithm could actually predict sepsis with acceptable sensitivity and specificity. No clinical trial data or validation results were ever published. The company's patents describe the algorithmic approach, but patents are not evidence of clinical efficacy.
This validation gap created a vicious cycle. Without clinical data, the company couldn't raise venture capital. Without capital, it couldn't fund the clinical studies needed to generate that data. The company was stuck in a pre-validation limbo that no amount of engineering effort could escape.
The contrast with Cytovale is instructive. Cytovale's IntelliSep test received FDA clearance, meaning it had the clinical evidence and regulatory approval that Sepsis Scout never achieved. When Cytovale acquired Sepsis Scout in October 2024, it was acquiring talent and intellectual property, not a validated product.[10]
The most important structural explanation for Sepsis Scout's failure is that its core approach—continuous wearable monitoring—was fundamentally mismatched with how sepsis is actually diagnosed and treated in clinical practice.
Sepsis is a medical emergency that requires immediate intervention. When a clinician suspects sepsis, they need a definitive answer in minutes, not a probabilistic alert from a wearable device. Cytovale's IntelliSep test provides sepsis risk in about 8 minutes from a standard blood draw.[13] This fits into existing clinical workflows: a patient presents with symptoms, a blood draw is ordered, and the test provides an actionable result.
A wearable-based approach faces a different set of challenges. The algorithm's output is probabilistic and requires interpretation. The clinical community has no established protocol for acting on a wearable alert. And the false positive rate—which could be high given the subtlety of pre-symptomatic sepsis signals—could erode clinician trust and create alert fatigue.
The market's verdict on these two approaches is visible in their funding trajectories. Cytovale raised $100M in Series D funding in October 2024, led by Sands Capital, to accelerate commercial expansion of its IntelliSep test.[14] Sepsis Scout's last funding was a $75K accelerator round and a $120K YC round, followed by a seed round and a government grant.[9][19] The market voted decisively for the blood-based approach.
The acquisition by Cytovale on October 23, 2024, was a talent and IP acquisition, not a product acquisition.[10] Robert Quinn joined Cytovale as Senior Medical Science Liaison, and his LinkedIn states he "Joined Cytovale as part of their acquisition of Sepsis Scout to be their Senior Medical Science Liaison."[13]
Cytovale's subsequent public communications about Quinn focused on his personal story, not Sepsis Scout's technology. In a February 2025 post on X, Cytovale wrote: "Robert Quinn, @Cytovale's Senior Medical Science Liaison, survived 18 episodes of #sepsis! Thanks to the quick actions of his friends and doctors, he's been able to fight it each time. Now at Cytovale, he's on a mission to fight sepsis with early detection."[18]
The framing is telling: Quinn's value to Cytovale was his personal story and clinical expertise, not Sepsis Scout's wearable technology. Quinn continued to publish on community-based sepsis detection, co-authoring a 2025 Lancet Primary Care viewpoint paper on "Preventing, identifying, and managing sepsis in the community."[17] He left Cytovale in 2026 to become an independent consultant.[12]
One could argue that Sepsis Scout was simply too early—that the market for at-home continuous monitoring will eventually emerge as wearable technology improves and remote patient monitoring becomes more established. Under this reading, the company's failure was a timing problem, not a fundamental flaw in the approach.
This argument has some merit. The infrastructure for remote patient monitoring has improved significantly since 2017. Consumer wearables have become more accurate and more widely adopted. Reimbursement for remote patient monitoring has expanded. A company building Sepsis Scout's product today might face a more receptive market.
But this counter-argument misses the deeper structural issue. Even with better wearables and more established remote monitoring, the fundamental challenge remains: sepsis is a medical emergency that requires immediate, definitive intervention. A probabilistic alert from a wearable device, without a confirmatory test, is unlikely to become the standard of care when a rapid blood test can provide a definitive answer in minutes. The market's preference for Cytovale's approach reflects this clinical reality, not just a timing difference.
The non-obvious structural mechanism in Sepsis Scout's failure is the mismatch between the company's capital structure and its regulatory requirements. Medical device startups face a fundamental tension: they need significant capital to fund clinical validation and FDA clearance, but investors are reluctant to provide that capital without evidence of clinical validation. This creates a chicken-and-egg problem that only well-funded teams or those with strategic partnerships can escape.
Sepsis Scout's $2.88M in funding was sufficient to build a prototype and file patents, but it was orders of magnitude below what was needed to navigate the regulatory pathway.[8] The company's participation in Y Combinator and MedTech Innovator provided mentorship and visibility but couldn't bridge this capital gap. The result was a company that existed for seven years, filed two patents, and was ultimately acquired for its talent and IP rather than its product.
This is a cautionary tale about the limits of the accelerator model for medical devices. Y Combinator's playbook—build fast, launch, iterate based on user feedback—works well for software startups with low regulatory barriers. It translates poorly to medical devices, where the path to market is measured in years and tens of millions of dollars, not months and engineering sprints.
Regulatory requirements are a business model, not a compliance burden. Sepsis Scout's product required FDA clearance to be commercially viable, but the company's funding ($2.88M) was a fraction of what FDA clearance typically costs.[8] Medical device founders must either raise capital commensurate with the regulatory pathway or find a business model that doesn't require regulatory approval. Sepsis Scout did neither.
Clinical validation is the moat, not the algorithm. Sepsis Scout's patents described an algorithmic approach to sepsis detection, but no clinical validation data was ever published. In medical technology, an algorithm without clinical evidence is a science project, not a product. Cytovale's FDA-cleared IntelliSep test had the clinical validation that Sepsis Scout lacked, which is why Cytovale raised $100M while Sepsis Scout was acquired for its talent.[14]
The accelerator model has limits for regulated industries. Y Combinator's Winter 2018 batch gave Sepsis Scout $120K and mentorship, but the accelerator's playbook—launch fast, iterate, find product-market fit—doesn't translate to medical devices where the path to market is measured in years and regulatory milestones.[2] Founders in regulated industries should be skeptical of applying software startup playbooks to their context.
A compelling founder story is not a business model. Quinn's 18 episodes of sepsis made for a powerful founding narrative, and Cytovale leveraged that story after the acquisition.[18] But the story couldn't substitute for clinical evidence, regulatory approval, or a path to revenue. Personal motivation is necessary for startup endurance, but it doesn't change the fundamental economics of medical device development.
The market's preferred solution may not be the technically elegant one. Sepsis Scout's wearable approach was technologically sophisticated, but the market preferred a rapid blood test that fit into existing clinical workflows. When a simpler, more established approach exists, a technically superior but unproven alternative faces an uphill battle regardless of its potential.
